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We have studied the formation of L-leucine nanoparticles under various conditions using an aerosol flow reactor method.
Temperatures and L-leucine concentrations for the experiments were selected to vary the saturation conditions for L-leucine
in the reactor. In the two extreme cases, L-leucine is either in (i) the condensed phase (110◦C) or completely in (ii) the vapour
phase (200◦C) for all concentrations; (iii) at the intermediate temperature (150◦C), the extent of evaporation of L-leucine depends
notably on the concentration, and thus partial evaporation and production of residual particles are expected. The size distribution
of particles and the particle morphology varied according to formation mechanism with the geometric mean diameter of the
particles between 30 nm and 210 nm. Hollow, spherical particles were obtained with the droplet-to-particle method without
vaporisation of L-leucine; whereas leafy-looking particles were produced by homogeneous nucleation of supersaturated L-leucine
vapour and subsequent growth by heterogeneous vapour deposition.
Copyright © 2008 Anna La¨hde et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The ability to design and produce pharmaceutical particles
with the desired surface properties by particle engineering or
by particle surface modification (e.g., coating) oﬀers a great
advantage in today’s market. Much study has been devoted
to the production of stable and dispersible dry-powder
aerosol formulations for eﬃcient pulmonary delivery of
pharmaceutical agents [1–3].
Amino acid L-leucine is an eﬀective excipient that
improves the properties of powder such as dispersibility,
flowability, and stability [2, 4–7]. Surface accumulation of
L-leucine on drug particle surfaces has been achieved by
powder blending [1, 2, 7], surface-diﬀusion in spray-drying
[5, 6] and physical vapour deposition (PVD) [4, 8]. Among
these techniques, the PVD method enables both eﬃcient
tailoring of the characteristics of an L-leucine particles and
preparation of the coating layers on the surface of the core
particles that aﬀects significantly the properties of coated
particles [4]. The interaction between particles can be further
reduced with the addition of L-leucine nanoparticles, that
is, glidants adsorbed on the surface of the micron-sized
particles. The glidants decrease the contact area between
particles and increase the separation distance depending on
the size and shape of the glidants [9, 10].
In the gas-phase methods including spray drying and
PVD, the particle size and shape are aﬀected by the formation
mechanism, that is, droplet-to-particle and gas-to-particle
conversion [8, 11]. Under suitable conditions these methods
enable the production of nanoparticles with well-defined
structure and size. The residence times in the heated zone
are short preventing the material decomposition [8]. Dry
nanoparticles are collected directly from the gas phase and
are available for use, for example, as glidants without further
purification or processing.
In our previous study of L-leucine particles, the evap-
oration of L-leucine took place from the aerosol L-leucine
particles whose mass median particle size was initially larger
than 0.8 μm [8]. In work presented in this paper, we have
extended the study to the particle sizes smaller than 0.8 μm.
The particle number concentrations in the studies are close
with only 13% diﬀerence in maximum. It is known that
the thermodynamic phenomena of material such as melting
and evaporation may change remarkably as particle size
decreases [12]. Accordingly, a rapid solvent evaporation from
the nanodroplets as well as the small initial size of the dry
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particles is likely to enhance the vaporisation of L-leucine due
to the Kelvin eﬀect [12]. As a consequence, the formation of
L-leucine nanoparticles in the later stage changes. We aim to
deepen the knowledge of L-leucine evaporation and particle
formation in the gas phase when L-leucine is introduced as
particles notably smaller than in our previous study.
2. MATERIALS AND METHODS
2.1. Materials
Pharmacopoeia grade L-leucine (Fluka Chem, grade PhEur,
Switzerland) was used as received. Prior to particle prepa-
ration, five aqueous L-leucine precursor solutions were
prepared by dissolving 1.1, 2.2, 4.3, 8.6, and 17.2 g of L-
leucine in 1 litre of ion-exchanged water (pH 6.5) at room
temperature.
2.2. Nanoparticle production
Figure 1 shows the experimental set-up of the reactor. The
precursor solution was atomised with a constant output
atomiser in the nonrecirculation mode (model 3076, TSI Inc.
Particle Instruments, USA) in the feeding Section 1 produc-
ing droplets around 300 nm estimated by the manufacturer.
A flow rate of 3.5 L/min of carrier gas (nitrogen, N2) was
used. The average feed rate of precursor solutions through
the atomiser was 0.4 mL/min controlled with a needle valve.
The actual L-leucine concentration in the reactor (Creactor)
was 0.012, 0.029, 0.065, 0.143, and 0.318 g/m3 depending
on the L-leucine precursor solution concentrations (Cle) 1.1,
2.2, 4.3, 8.6, and 17.2 g/L, respectively, since only fraction of
the droplets with suitable size is carried to the heated zone
(Section 2) while the excess liquid is collected to the waste
bottle (Figure 1).
After atomisation, the droplets were carried to the heated
zone (Section 2) of the reactor, which consisted of a stainless
steel tube (inner diameter of 30 mm and length of 1200 mm)
placed inside the furnace. The flow in the heated zone
was fully laminar. Experiments were carried out at three
temperatures 110, 150, and 200◦C (±◦C); and the average
residence times in the heated part were 11.1, 10.1, and
9.0 s, respectively. The average residence time t (second) was
calculated using the temperature corrected volume flow rate
Q (m3/s) the cross-sectional area of the tube A (m2) and the
length of the heated zone L(m) : t = (Q×1)/A. The centreline
gas temperatures of the reactor tube were measured with
the gas flow at 5 cm intervals with a K-type thermocouple.
These temperatures were used in the calculations described
in Section 2.4.1.
The aerosol exiting the heated zone was rapidly cooled
with a large volume of N2 at ambient temperature at a flow
rate of 30 L/min using a porous tube (sintered metal tube
with pore size 20 μm). The length of the porous tube was
200 mm with inner diameter of 12.7 mm. In Section 3, the
nucleation and subsequent condensation of L-leucine vapour
was initiated. The simultaneous cooling and dilution with
a dilution ratio of 9.6 : 1 prevented solvent condensation
and decreased the wall deposition losses of dry L-leucine
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Figure 1: The experimental of the aerosol flow reactor used in the
particle production.
particles. Complete mixing of aerosol and dilution gas before
particle sampling was ensured with a mixing tube with
an inner diameter of 9.6 mm and length of 250 mm. The
flow Reynolds number in the diluter and the mixing tube
(Re∼4550) indicated turbulent flow.
2.3. Instrumentation and characterisation
The particle number size distributions were measured with
a diﬀerential mobility analyser, DMA (model 3081, TSI Inc.
Particle Instruments, USA) connected to a condensation
nucleus counter, CPC (model 3022, TSI Inc. Particle Instru-
ments, USA). Particle samples were collected with a point-to-
plate electrostatic precipitator, ESP (InTox Products, USA)
on carbon-coated copper grids. The morphology of the
particles was studied with a transmission electron micro-
scope, TEM (Philips CM-200, FEG/STEM, FEI Company,
The Netherlands) and a field-emission low-voltage scanning
electron microscope, FE-SEM (Leo Gemini DSM982, Leo
Electron Microscopy Inc., Germany). The crystallinity of
the individual particles was analysed from the electron
diﬀraction patterns by TEM. For the SEM imaging, the
samples were coated with platinum to increase the stability
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Table 1: Characteristics of L-leucine nanoparticles produced using diﬀerent precursor solution concentrations and at diﬀerent temperatures
in the reactor heated zone.
Cle [g/l] Creactor [g/m3]
Treactor = 110◦C Treactor = 150◦C Treactor = 200◦C
S′max dg [nm] dm [nm] GSD N [1/cm
3] S′max dg [nm] GSD N [1/cm
3] S′max dg [nm] GSD N [1/cm
3]
1.1 0.012 38 99 418 2.0 5.8× 105 0.48 31 1.8 2.7× 105 0.0058 28 1.7 1.9× 105
2.2 0.029 93 123 520 2.0 8.1× 105 1.16 61 1.5 5.1× 105 0.014 35 1.5 3.5× 105
4.3 0.065 208 135 571 2.0 7.8× 105 2.61 105 1.4 3.6× 105 0.032 63 1.8 6.5× 105
8.6 0.143 455 142 600 2.0 6.9× 105 5.79 180 1.5 3.1× 105 0.070 109 1.9 6.7× 105
17.2 0.318 1020 150 782 2.1 8.2× 105 12.8 209 1.7 3.4× 105 0.16 162 1.9 1.7× 106
Cle is leucine concentration in the precursor solution, Creactor is the actual leucine concentration in the reactor, Treactor is the temperature in the heated zone,
S′max is a descriptive saturation ratio (not a real condition) that would be obtained, if all L-leucine was in the vapour phase under these conditions, dg is the
geometric mean diameter, dm is the mass median diameter calculated from dg using a Hatch-Choate conversion equation for log-normal size distributions
given in literature [17], GSD is the geometric standard deviation, and N is the particle number concentration.
of the particles in the electron beam. The chemical identity
of the L-leucine powder before and after the experiments was
studied with 1H- and 13C-NMR (200 MHz Varian Gemini
2000, Varian Inc. Corporate, USA) using D2O as the solvent.
The NMR studies confirmed that the chemical composition
of L-leucine did not change during the particle production.
2.4. Reactor conditions
2.4.1. Saturation ratio of L-leucine in the reactor
The vapour pressure and saturation ratio of L-leucine in the
reactor were calculated using the enthalpy of sublimation
(ΔHsub = 150.7 kJ/mol at Tsub = 455 K) according to Svec
and Clyde [13]; and it is described in detail in the article of
Raula et al. [8]. The vapour pressure and saturation ratio of
water in the reactor were calculated using same method and
using the saturation vapour pressure of water given in the
literature [14]. The saturation ratios of water remained well
below zero (2×10−7) for all reactor conditions including the
cooling section of the reactor.
2.4.2. Vaporisation of L-leucine from the dry
particles in the heated zone
The evaporation time of L-leucine from the dry particles
(i.e. particles contain no water) in the heated zone of the
reactor was estimated using a diﬀusional transport equation
according to Flagan and Seinfeld [15]:
dDp
dt
= 4DvM
RρpTDp
(
pinf − pps
)
βFS, (1)
where Dp is the particle diameter, t is time, Dv is the diﬀusion
coeﬃcient of the L-leucine vapour, M is the molecular weight
of L-leucine, R is the gas constant, ρp is the particle density,
T is the reactor temperature, pinf is the L-leucine vapour
pressure in the environment far away from the particle, pps
is the vapour pressure over the particle surface, and βFS
is the Fuchs-Sutugin interpolation factor for bridging the
equations for continuum and the free molecular regions
during the particle size change due to evaporation of L-
leucine as described by Fuchs and Sutugin [16]. pinf is
calculated based on the transfer of L-leucine to the gas
phase by vaporisation of the particle and it is assumed to
be zero at the beginning of calculations. The size (dg) and
number concentration (N) of L-leucine particles produced
at 110◦C were used as the input in the calculations. The
particles were assumed to be spheres with monodisperse
size distribution (GSD = 1). In (1), the particle diameter
(Dp) is the mass median diameter (dm). Accordingly, the
geometric number mean diameters were converted using
a Hatch-Choate conversion equation (HC) [17] into mass
median diameters (see Table 1) that were used as the initial
particle diameters (dmi). This gives slight overestimate of
the mass median diameter. The number of particles was the
average of the particle concentrations (N = 7.4× 105 1/cm3)
and it was used together with dm to calculate iteratively
pinf . The particle density was assumed to be the same as
the density of crystalline L-leucine (1.293 g/cm3) given in
literature [18]. No wall losses were taken in to account in the
calculations. The amount of L-leucine vapour in the heated
zone increases as the particle size decreases with time in
the calculations as long as the saturation vapour pressure is
reached. Instantaneous and perfect mixing is assumed in the
calculations.
Fuchs-Sutugin interpolation factor βFS is calculated as
βFS = 1 + Kn
1 + 1.71× Kn + 1.333× Kn2 , (2)
where Kn is a Knudsen number for the particle and is
calculated iteratively for the decreasing particle size with the
following equation:
Kn = 2λ
Dp
. (3)
The diﬀusion coeﬃcient of the vapour was estimated using
the equation derived from literature [17]:
Dv = 2
3nd2c
√
RT
π3M
, (4)
where n is the number of vapour molecules taken to be the
same as the number of gas molecules (2.5 × 1025 1/m3) and
dc is the collision diameter of the molecule that is considered
to be the same as the diameter of the molecule that is 6.8 A˚
derived from the literature [19].
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The Kelvin eﬀect expresses the increase in vapour pres-
sure over a curved surface. The vapour pressure over the
particle surface (pps) is the product of the vapour pressure
over the flat surface (ps):
pps = ps exp
(
4γM
ρpRTDp
)
, (5)
where γ is surface tension or surface free energy. Since
there are no data available on the surface free energy of L-
leucine, the surface tension of the 17.2 g/L aqueous solution
of L-leucine was used instead. This concentration is very
close to the solubility limit of L-leucine in ion-exchanged
water. The measured surface tension of the L-leucine solution
(67 mN/m) agrees well with the literature values of Glin´ski
et al. [20]. A similar assumption is also made in studies of
Lechuga-Ballesteros and Kuo [6].
3. RESULTS
3.1. Reactor conditions
Figure 2 shows the vapour pressures of L-leucine in the
reactor at concentrations between 0.012 and 0.32 g/m3 as
well as the equilibrium vapour pressure of L-leucine in the
temperature range 120 and 200◦C calculated using equations
and methods introduced by Raula et al. [8]. Accordingly,
the evaporation of L-leucine begins when the temperature
is raised above 140◦C; and L-leucine is completely vaporised
in all concentrations when the temperature is above 180◦C
within the studied concentration range. An infinite residence
time is assumed in these calculations. Table 1 lists the
saturation ratios (S′max) for the diﬀerent concentrations of
L-leucine assuming that all L-leucine is vaporised. S′max > 1
indicates how far the condition in the heated zone is from the
actual L-leucine vaporisation.
In the cooling zone, the cooling rates of the aerosol were
210 and 293◦C/s from 150 and 200◦C to ambient tempera-
ture (T = 22◦C). The rapid cooling induced a sudden change
in saturation conditions leading to the supersaturation of L-
leucine vapour. This resulted in saturation ratios temporarily
far above unity (from 24.8 to 310) based on calculations of
saturation ratios using equations and methods introduced in
Raula et al. [8]. Instantaneous perfect mixing was assumed;
and the possible temperature gradient between the centre
line and the walls was not taken into account.
3.2. Vaporisation of L-leucine from the dry
particles in the heated zone
Figures 3(a) and 3(b) show the change in size of the particles
due to the evaporation of L-leucine at 150 and 200◦C. In
general, the time needed for the particle size to reach an
equilibrium state was short compared to the residence time
in the heated zone of the reactor. At 200◦C, the time needed
for complete evaporation ranged from 11 to 38 milliseconds
for particle sizes of 418 and 782 nm, respectively (see
Figure 3(b)). The reduction rate of the particle size decreased
from 38 to 20 nm/ms as the initial particle size increased from
418 to 782 nm.
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Figure 2: Vapour pressures and saturation vapour pressures (ps)
L-leucine under diﬀerent experimental conditions.
Based on the estimated saturation ratio (0.48) for L-
leucine at 150◦C calculated according to Raula et al. [8] L-
leucine was expected to vaporise completely at the lowest
concentration (Creactor of 0.012 g/m3). However the calcula-
tions with the diﬀusional transport equation (1) showed only
partial vaporisation producing residual particles of 260 nm,
see Table 2. The time required to reach equilibrium size
was notably longer than at 200◦C varying from 3 to 0.8
seconds for particle sizes of 418 and 782 nm, respectively.
According to the calculations, complete evaporation of L-
leucine with initial particle size of 418 nm corresponding
to a concentration of 0.012 g/m3 took place at 157◦C in
606 milliseconds.
3.3. Number size distributions
Table 1 shows the characteristics of the particles produced at
diﬀerent reactor temperatures and L-leucine concentrations
(Creactor). The size distributions of particles produced at
110◦C are shown in Figure 4. At 110◦C, the solute droplets
were merely dried. The geometric number mean diameter
(dg) of the particles increased from 99 to 150 nm with
increasing L-leucine concentration (Table 1). The GSDs were
around 2 at every concentration. The number concentration
of particles (N) varied only slightly between the experiments
and was on average 7.4 × 105 L/cm3. The size distributions
were unimodal and close to symmetrical, that is, dg was very
close to the count median diameter (CMD) obtained in the
measurements with only a few nanometres diﬀerence in all
cases. Therefore, the corresponding mass mean diameters
of the size distribution (see Table 1) were calculated with
Hatch-Choate equation described by Hinds [17].
Figure 5 shows the number size distributions of the
L-leucine particles produced at 150◦C. According to the
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Figure 3: Calculated size reduction of L-leucine particles with diﬀerent initial particle size as a function of time at (a) 150◦C and (b) 200◦C.
Table 2: The comparison of the vaporisation of L-leucine from the particles in the heated zone of the reactor in the current and previous
study of Raula et al. [8]. Experimentally derived particle number concentrations in the calculations were 7.4×105 in this study and 8.5×105
in Raula et al. [8].
This study Raula et al. [8]
Creactor [g/m3] 0.012 0.029 0.065 0.143 0.318 0.02 0.09 0.22 1.34
dm [μm] 0.42 0.52 0.57 0.60 0.78 0.80 1.35 1.69 2.41
dres at 150◦C [μm] 0.26 0.44 0.50 0.54 0.75 0.78 1.34 1.69 2.4
Time needed for complete
10.9 16.6 19.9 22.0 38.4 41.4 278.9 n.a. n.a.
vaporisation at 200◦C [ms]
N is the number of particles in the calculations for all concentrations, dm is the mass median diameter at 110◦C calculated from dg using a Hatch-Choate
conversion equation for log-normal size distributions given in literature [17], dres is the size of the residual particles obtained from the calculation with (1),
n.a. = not applicable.
calculated saturation ratio, L-leucine was completely vapor-
ised only with the lowest concentration of L-leucine, that
is 0.012 g/m3, while at higher concentrations than that, L-
leucine was partially vaporised. dg of the particles increased
from 31 to 209 nm with increasing L-leucine concentration
and the GSD varied between 1.4 and 1.8. N did not change
notably with respect to the L-leucine concentration and was
between 2.7×105 and 5.1×105 L/cm3. The size distributions
were close to log-normal except for the highest concentration
where a bimodal distribution was obtained.
Figure 6 shows the number size distributions of the
particles from the reactor at 200◦C, where L-leucine was
completely vaporised at all concentrations according to S
(see Figure 2). dg of the particles increased from 28 to 162
nm and N increased from 1.9 × 105 to 1.7 × 106 L/cm3 with
increasing L-leucine concentration. With the two lowest L-
leucine concentrations, the size distributions were unimodal.
With Creactor of 0.065 g/m3 and above, bimodality in the
distributions was observed.
3.4. Shape and structure of L-leucine nanoparticles
Figures 7(a) and 8(a) show SEM images of L-leucine
nanoparticles produced with the highest concentration of
L-leucine (0.32 g/m3) from the reactor at 110 and 150◦C,
respectively. The sizes of the particles are in a good agreement
with volume-based median diameters calculated by Hatch-
Choate conversion equations [17]: the diameters ranged
from 418 to 782 nm. In both cases, the particles appeared
collapsed and partially fractured indicating that particles are
produced by droplet drying. TEM images (Figures 7(b) and
8(b)) show relatively low contrast in the central areas of
the particles so that the supporting film underneath can be
clearly seen. For this to happen with this size of particles, the
particle shell has to be very thin which indicates low particle
density. Figures 9(a) and 9(b) show the SEM and TEM
images, respectively, of L-leucine nanoparticles produced at
the highest concentration (0.32 g/m3) with the temperature
of the heated zone at 200◦C. At this temperature L-leucine
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Figure 4: Number size distributions of L-leucine particles produced
from the reactor at 110◦C. L-leucine concentration varied from
0.012 to 0.32 g/m3.
100010010
Particle diameter (nm)
0.012 g/m3
0.029 g/m3
0.065 g/m3
0.143 g/m3
0.318 g/m3
0
2
4
6
8
10
12
×105
dN
/d
lo
gD
p
(1
/c
m
3
)
Figure 5: Number size distributions of L-leucine particles produced
from the reactor at 150◦C. L-leucine concentration varied from
0.012 to 0.32 g/m3.
vaporises and the particles were formed by the nucleation
and condensation of the L-leucine vapour. The particles had
a light, leafy-looking structure that is clearly diﬀerent from
the particle structures obtained at lower temperatures.
Electron diﬀraction patterns taken from a population of
particles in TEM are shown as inserts in the corresponding
TEM images (Figures 6–8(b)). The diﬀraction patterns
indicate that the particles are crystalline despite the weak
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Figure 6: Number size distributions of L-leucine particles produced
from the reactor at 200◦C. L-leucine concentration varied from
0.012 to 0.32 g/m3.
contrast due to the deterioration of particles within a few
seconds under the electron beam.
4. DISCUSSION
4.1. Vaporisation of L-leucine depending on
the particle size and temperature
Table 2 shows the amount of L-leucine fed to the reactor
and the changes in particle size due to the vaporisation of
L-leucine calculated in this study and compared with the
values of the previous study of Raula et al. [8]. Even though
the particle number concentrations are of the same order
of magnitude with only 13% diﬀerence, the initial droplet
size in the experiments is considerably diﬀerent. According
to the manufacturer (TSI), the droplets around 300 nm are
produced with the atomizer used in this study whereas the
ultrasonic atomizer used by Raula et al. [8] generates micron-
sized droplets. This in turn aﬀects the dry particle size as well
as the amount of L-leucine vapour in the heated zone of the
reactor.
According to the calculations at 150◦C, no vaporisation
of L-leucine was observed with particles larger than 0.75 μm,
that is, in the study of Raula et al. [8] and the largest particle
size in this study. Below 0.75 μm, the calculations showed
the partial vaporisation of L-leucine and formation of the
residual particles with the mass median diameters (dres) 0.26,
0.44, 0.50, and 0.54 μm (Table 2). The partial vaporisation
observed even with the smallest particle size correspond-
ing to the lowest concentration is in contradiction with
the saturation ratio that predicted complete vaporisation
(Table 1). Since the amount of L-leucine in the reactor was
derived from the total number of particles, particle size,
and density as described in Section 2.4.2, the calculation is
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Figure 7: (a) SEM and (b) TEM images of L-leucine particles pro-
duced at 110◦C. Electron diﬀraction pattern indicating crystallinity
is inserted in (b).
likely to give a slight overestimation of the amount of L-
leucine in the reactor. One reason for this is the density
value of crystalline bulk L-leucine used in the calculations
compared to the hollow particle structure observed in TEM
images. The repetition of the calculations at temperature of
157◦C showed full vaporisation of L-leucine at the lowest
concentration (0.012 g/m3). This indicates that saturated
conditions are close and only small variations may aﬀect
particle formation in these conditions.
A complete vaporisation of L-leucine was observed
at 200◦C for particles smaller than 1.69 μm. The time
needed for the vaporisation increased exponentially with
increasing particle size as the mass of L-leucine increased.
The vaporisation of L-leucine decreases the particle size
and it further accelerates the rate of vaporisation of the
particles (see Figure 3(b)). This is understood by the Kelvin
eﬀect, which means that thermal transitions like melting and
vaporisation of material requires less energy when particle
size decreases [21–24]. For particles composed of organic
material the Kelvin eﬀect can be significant for particle sizes
up to 200 nm [12].
4.2. Formation of dry L-leucine particles
At 110◦C, the particles were formed by droplet drying and
the cooling of the aerosol did not aﬀect the formation of the
particles or the resulting particle size and size distribution.
During the solvent evaporation, L-leucine accumulated on
an air-water interface that, in this study, is the surface of the
droplets. L-leucine is also known to spontaneously assemble
as structured aggregates at the interfaces of the aqueous
solution as described by Weissbuch et al. [25]. The rapid
formation of the L-leucine surface layer caused the pressure
build-up by the vaporisation of water expanding the surface
layer. This resulted hollow, collapsed, and fractured particles
with low density as observed also in the study of Raula et al.
[8]. The volume-based median diameters of the particles
coincide well with the observed particles.
The layer formation notably aﬀected the size of L-leucine
particles produced with a droplet-to-particle method at
110◦C. Let us assume that L-leucine particles are spherical
with the density of crystalline L-leucine (1.293 g/cm3).
1μm
(a)
1μm
(b)
Figure 8: (a) SEM and (b) TEM images of L-leucine particles pro-
duced at 150◦C. Electron diﬀraction pattern indicating crystallinity
is inserted in (b).
2μm
(a)
0.5μm
(b)
Figure 9: (a) SEM and (b) TEM images of L-leucine particles pro-
duced at 200◦C. Electron diﬀraction pattern indicating crystallinity
is inserted in (b).
According to the manufacturer, the atomizer generates water
droplets with diameter around 300 nm. Based on these
data, the sizes of the solid, spherical L-leucine particles for
every solution concentration can be calculated. The diameter
of the particles at a concentration of 0.012 g/m3 was 3.6
times larger than the calculated size. The increase in the
particle size was evidently caused by the expansion of the
particle surface layer as discussed above. The size diﬀerence
decreased with increasing L-leucine concentration, but was
still 2.1 at the highest L-leucine concentration, 0.32 g/m3.
This indicates a very low density of the particles. The micron-
sized porous particles with the density as low as 0.4 g/cm3
has been previously prepared by emulsification and solvent
evaporation by Edwards et al. [26].
At 200◦C, L-leucine fully evaporated in the reactor at
all concentrations. High supersaturation and subsequent
homogeneous nucleation of the L-leucine vapour were
obtained in the cooling zone. During the vapour deposition
on the surface of the nuclei, L-leucine formed leafy-looking
crystallites with sizes of a few nanometres with similar
morphology of particles than observed by Raula et al.
[8]. The heterogeneous deposition of L-leucine vapour is
preferred on discontinuous spots such as edges and corners
if present as studied by Rogers and Yau [27]. Apparently, the
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discontinuous domains for heterogeneous nucleation were
created at the very beginning of the formation of stable nuclei
by homogeneous nucleation of vapour resulting in crystal
growth in a certain direction (see Figure 9). The number size
distribution of the resulting particles was relatively narrow
and unimodal at low L-leucine concentrations. The particle
size was more dependent on the L-leucine concentration
and it varied from 28 nm up to 162 nm compared to the
particles prepared by Raula et al. [8] at 200◦C with geometric
mean diameters close to 100 nm in all cases except at the
lowest concentration. Increasing the vapour concentration
resulted in the appearance of shoulders in the distribution.
This indicated that several nucleation modes were occurring
along the cooling of the L-leucine vapour. There could
be several reasons for that such as the trace amounts of
unvaporised impurities in the precursor solution. Another
reason is the temperature gradient in the cooling zone that
was caused by the introduction of ambient nitrogen through
the porous tube, that is, through the tube walls. The bimodal
size distribution obtained at the high supersaturations of L-
leucine vapour was due to the nonuniform temperature field
and turbulent flow profile in the cooling and mixing zone as
well as due to the slow diﬀusion of L-leucine vapour.
At the intermediate temperature of 150◦C, the extent of
evaporation of L-leucine depended on the concentration as
discussed in Sections 3.2 and 4.1. The saturated conditions
are close and only small variations may aﬀect particle
formation. In fact, the size of the particles produced at
the lowest concentration (dg = 31 nm) agreed well with
the size obtained at 200◦C with the same concentration
and strongly indicated particle formation purely by vapour
nucleation. The reactor conditions for L-leucine became
saturated above a concentration of 0.037 g/m3 corresponding
to 2.0 g/L, at which the saturation ratio was unity. A fraction
of the vaporised L-leucine (0.037 g/m3) was deposited on the
surface of the residual, unvaporised solid L-leucine particles
via heterogeneous vapour deposition. The particle size was
clearly dependent on both the L-leucine concentration and
on the vapour deposition of the L-leucine vapour on the
residual particles. Narrow-size distributions (GSD∼1.4-1.5)
were the result of the eﬀective heterogeneous vapour depo-
sition of L-leucine. In heterogeneous condensation/vapour
deposition, which is the reverse of size decrease by evap-
oration described in (1), the smaller particles grow faster
compared to larger particles narrowing the size distribution
as described by Hinds [17]. However, the small amount of
L-leucine vapour deposited on the particle surfaces was not a
major factor determining the particle size at high L-leucine
concentrations (0.14 and 0.32 g/m3). These concentrations
yielded particle sizes larger than those produced at 110◦C
as summarised in Table 1. This diﬀerence in size can be
explained by the formation of the L-leucine layer on the
droplet surface that increased vapour pressure of the solvent
water inside the droplet with the elevated temperature in
the heated zone. This led to further expansion of the L-
leucine surface layer during drying. The second mode as a
shoulder in the size distribution at 0.32 g/m3 in the reactor
at 150◦C may denote the appearance of fractured particles as
was observed also in SEM images (Figure 8).
5. CONCLUSIONS
The production and formation of L-leucine nanoparticles
under various conditions have been studied using the
aerosol flow reactor method. The particle formation and
growth mechanisms depended on the L-leucine saturation
conditions in the reactor. At 110◦C, low-density particles
were formed by droplet drying. The particle size was
determined solely by the precursor solution concentration
with dg between 99 and 150 nm. At 15◦C, L-leucine was
partially vaporised and some unvaporised material remained
in residual particles. The particle size increased from 31 nm
up to 209 nm. The particle size depended not only on the pre-
cursor solution concentration but also on the heterogeneous
condensation of L-leucine vapour on the residual particles.
At 200◦C, L-leucine was entirely vaporised at all precursor
concentrations and the particle size varied from 30 nm to
210 nm. The vaporisation of L-leucine was faster compared
to the previous studies. Furthermore, the particle size was
more dependent on the amount of L-leucine in the reactor.
The particles were formed by homogeneous nucleation of L-
leucine vapour causing the formation of leaf-like, crystalline
nanoparticles as also observed previously.
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